Latest Breaking News On - Mark wuttke - Page 1 : comparemela.com

Topline results show MyopiaX light stimulation safe, tolerable in children

Dopavision has announced positive topline results from a proof-of-concept trial of MyopiaX, a noninvasive photobiomodulation intervention designed to slow myopia progression in children.“The 6-month outcomes represent a significant step in the clinical development of MyopiaX,” Ian Flitcroft, PhD, FRCOphth, coordinating investigator of the MyopiaX-1 trial, said in a company press

Dopavision Announces Topline Results in Clinical Trial of Targeted Photobiomodulation Approach for Progressive Myopia

Safe and Tolerable: MyopiaX-1 proof-of-concept clinical trial (NCT04967287) supports MyopiaX's excellent safety and tolerability profile with no untoward safety events. Novel Approach: Dopavision's

Dopavision Reports Successful Completion of Enrollment for MyopiaX-1 Trial

- MyopiaX-1 trial to generate first clinical evidence with MyopiaX®,a novel therapeutic approach to manage myopia progression

Dopavision Reports Successful Completion of Enrollment for

- MyopiaX-1 trial to generate first clinical evidence with MyopiaX®, a novel therapeutic approach to manage myopia progression- First data readout expected.

Enrollment complete for study of MyopiaX app in children, adolescents